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Abstract
Background: Emotional disorders, which include both anxiety and depressive disorders, are the most prevalent
psychological disorders according to recent epidemiological studies. Consequently, public costs associated with their
treatment have become a matter of concern for public health systems, which face long waiting lists. Because of their
high prevalence in the population, finding an effective treatment for emotional disorders has become a key goal of
today’s clinical psychology. The Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders might serve
the aforementioned purpose, as it can be applied to a variety of disorders simultaneously and it can be
easily performed in a group format.
Methods: The study is a multicenter, randomized, non-inferiority controlled clinical trial. Participants will be 220
individuals with emotional disorders, who are randomized to either a treatment as usual (individual cognitive
behavioral therapy) or to a Unified Protocol condition in group format. Depression, anxiety, and diagnostic criteria are
the primary outcome measures. Secondary measures include the assessment of positive and negative affect, anxiety
control, personality traits, overall adjustment, and quality of life. An analysis of treatment satisfaction is also conducted.
Assessment points include baseline, post-treatment, and three follow-ups at 3, 6, and 12 months. To control for missing
data and possible biases, intention-to-treat and per-protocol analyses will be performed.
Discussion: This is the first randomized, controlled clinical trial to test the effectiveness of a transdiagnostic
intervention in a group format for the treatment of emotional disorders in public settings in Spain. Results obtained
from this study may have important clinical, social, and economic implications for public mental health settings in
Spain.
Trial registration: Retrospectively registered at https://clinicaltrials.gov/. Trial NCT03064477 (March 10, 2017). The trial is
active and recruitment is ongoing. Recruitment is expected to finish by January 2020.
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Background
Emotional disorders (EDs; i.e., depressive and anxiety
disorders) have become the most prevalent psychiatric
disorders globally [1]. The 12-month prevalence of anx-
iety and depressive disorders affect 14% and 7.8% (6.9%
by major depression) of the population, respectively [2],
and comordibity may be as high as 50% [3]. Lifetime
prevalence rates in primary care settings in Spain reveal
that mood and anxiety disorders, as defined in the
DSM-IV-TR) [4], are the most prevalent psychiatric
problems as well, with 35.8% and 25.6%, respectively [5].
As a result of their high prevalence in the population,
EDs have become a global health problem due to their
associated costs. For instance, a study conducted in 36
countries estimated that the annual treatment cost of
depressive disorders and anxiety problems amounted to
$91 billion and $56 billion, respectively [6]. It has been
calculated that more than 12 billion days of productivity
loss are attributable to depression and anxiety disorders
every year, which results in $925 billion in productivity
losses. In Spain, when direct and indirect costs are in-
cluded, mood and anxiety disorders (again, according to
DMS-IV-TR categories), are estimated to cost approxi-
mately $10.76 billion and $10.36 billion, respectively [7].
The high prevalence and important burden of EDs indi-
cate that there is an urgent need to enhance the effect-
iveness of treatments for EDs in public mental health
systems.
The Unified Protocol (UP) for the Treatment of Emo-
tional Disorders [8, 9] is a recently developed form of
cognitive behavioral therapy (CBT).The UP can be
applied to a variety of disorders simultaneously and it
can be easily performed in a group format. The UP was
created on the basis of the identification of common
psychopathological vulnerability factors in EDs [1, 10].In
the UP, traditional CBT techniques (i.e., cognitive
restructuring) are combined with more novel psycho-
logical skills (i.e., increasing awareness) to treat emotion
regulation deficits, which are argued to be the under-
lying common factors in all EDs [11]. The UP is a struc-
tured, manual-based treatment [8, 9] which facilitates
group delivery when patients present different EDs [11].
This, together with the fact that the UP can be applied
simultaneously to individuals with different EDs, might
help reduce existent waiting lists and current costs of
individual treatment.
So far, studies exploring the effectiveness of the UP in
a group format have led to promising findings [12–
15].Overall, results suggest that the UP obtains medium-
to-large effect sizes on numerous outcomes, including
depression, anxiety, positive and negative affect, quality
of life, overall adjustment, and avoidance of negative
sensations, for both anxiety and mood disorders [12–
14]. These studies have also revealed that between half
and two thirds of patients ceased to meet diagnostic
criteria after the treatment and one investigation, con-
ducted by our team, revealed that changes remained
stable 12 months after treatment completion [13]. Des-
pite the previous results are encouraging, conclusions
should be interpreted with caution as sample sizes have
been small (11 participants in two studies and 47
patients in one investigation). Methodologically-sound,
randomized, controlled trials are needed in order to rep-
licate the aforementioned findings and to elucidate
whether the UP in group format is indeed an effective
treatment option for EDs in public settings.
The present non-inferiority, randomized, controlled
trial will compare the efficacy of the UP in group format
against traditional individual CBT treatment in a sample
of patients with EDs. Ultimately, our goal is to explore
whether the UP in group format can be an effective psy-
chological intervention for EDs in the Spanish National
Health System, that is, one that generates long-lasting
changes in symptoms. To ensure the generalizability of
results, our goal is tested in various public mental health
centers in Spain.
Methods/design
The current study is a non-inferiority, multicenter,
randomized, controlled clinical trial with two treatment
groups: UP in group format and traditional CBT in indi-
vidual format (treatment as usual, TAU). A conservative,
non-inferiority design was selected because, to the best
of our knowledge, this is the first randomized controlled
trial to compare the UP in a group format against indi-
vidual CBT in public mental health settings.
In the present investigation, all consecutive patients
with EDs attending any of the collaborating centers (see
“Sample and recruitment” section) are asked to partici-
pate. Once inclusion criteria are met (see “Inclusion and
exclusion criteria” section), each patient is randomly
assigned to one of the two experimental groups: TAU or
UP (see “Procedure” section). The study includes 5
assessment points (baseline, post-treatment, and three
follow-ups at 3, 6, and 12 months after treatment com-
pletion). The flow chart of study design is shown in Fig.
1. Also, a schedule of enrolment, interventions, and
assessments is reported following the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) guidelines (Fig. 2). Note that, despite treatment
occurs at different frequencies between conditions (ap-
proximately once a month in the TAU condition and
weekly in the UP group), assessment points are the same
for both groups.
Sample and recruitment
The trial started the recruitment in September 2014 and
it is still active. The study is conducted in five different
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Public Mental Health Centers and Primary Care Centers
in Spain, namely, the Elda Clinical General Hospital, the
Hospital Clínico Universitario de Valencia, the Dr. Peset
University Hospital, the PCC IIA Milagrosa of Pamplona,
and the Hospital Comarcal de Vinaròs. Participants are in-
dividuals over 18 years of age seeking psychological assist-
ance in the Spanish Public Health System. Sample size
was set to 220 participants to ensure enough statistical
power when testing our hypotheses (see “Sample size”
section).
Patients are referred to the study by licensed psycholo-
gists, psychiatrists, and clinical psychology residents
working at the collaborating centers, who also assess for
current DSM diagnoses (See “measures” section) and the
remaining eligibility criteria (see “Inclusion and exclu-
sion criteria” section). Individuals with comorbid diagno-
sis of several EDs are also enrolled in the study. The
existence of such comorbidities might be important for
assessment scores. However, in the present study we did
not stratify considering comorbidities because this could
significantly increase the complexity of the design (i.e.,
some patients might have more than one comorbid diag-
nosis). Due to the difficulties derived from conducting
an RCT in different public mental health settings, we
cannot guarantee a 100% of independent evaluations.
We expect between 60 to 75% of independent evalua-
tions. The rest of evaluations will probably be made by
recruiters who are also the therapists in one of the
conditions. However, this information is collected and
considered in the interpretation of results.
Patients meeting eligibility criteria are asked to partici-
pate and are provided with an information sheet, infor-
mation on data confidentiality, and an informed consent
form. After participation acceptance, patients complete
the baseline assessment protocol in their correspondent
health center (see “Measures” section). Next, partici-
pants are informed of the condition they have been ran-
domly assigned to, that is, TAU or UP.
Enrollment period and waiting time are comparable
across participants (2–3 weeks). When the time from
assessment, diagnosis, and randomization to the onset of
the intervention takes more than 2 weeks we establish a
new period of assessment. For ethical reasons, if a
patient feels uncomfortable with the group format at any
time during the study, he/she is allowed to join the TAU
condition. This information is collected and considered
in the analyses.
Sample size
To calculate the sample size required, the non-inferiority
margin (i.e., tolerable amount of effect difference
between TAU and the UP) has to be set. This was done
according to the US Food and Drug Administration
(FAD) [16] guidelines. First, the effect of the active
control (i.e., CBT) compared with placebo needs to be
established, based on previous research. Meta-analyses
Fig. 1 Study flow chart
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indicate medium-to-large effect sizes (between .4 and
.8) of individual CBT on EDs [17–19]. Then, an
amount of minimum preserved effect needs to be set.
According to FDA guidelines, a preserved effect of a
50% of the effect of the active control (individual
CBT) is recommended, so this was set to .3 in the
present study. Because, to the best of our knowledge,
no meta-analysis has reported effect sizes for each
outcome included in the study, the margin has been
defined according to the pooled estimate of overall
effectiveness of CBT.
With regards to treatment satisfaction, a 35% non-
inferiority margin was established. This is based on a
meta-analysis of computer CBT, in which between 70%
and 100% of depressed patients were satisfied with
treatment [20]. To the best of our knowledge, there is
no meta-analysis of treatment satisfaction with individ-
ual, face-to-face CBT and its study is rare. However,
similar to group UP, computer CBT has been argued to
be an alternative to traditional CBT [20], especially when
resources are limited, so the aforementioned satisfaction
rates of computer CBT might be relevant in the present
study.
We obtained a sample size of 95 participants for
each group with 80% power, an alpha level of .05
(one-sided), a standard deviation of .83 in the CBT
group compared with placebo, and a non-inferiority
limit of .30 [21, 22]. Considering a drop-out of 15%,
we decided to recruit 110 subjects in each group.
When registering the study, a sample size of 200
STUDY PERIOD
Enrolment
Pre-
allocation
Allocation
Post-allocation
Close-out
TIMEPOINT -t1
t0
Baseline
t1
t2
Post-treatment
t3
Follow-up 3
t4
Follow-up 6
t5
Follow-up 12
ENROLMENT:
Eligibility screen: X
ADIS-IV-L X X X X X
Informed consent X
ALLOCATION: X
BDI-II X X X X X
BAI X X X X X
INTERVENTIONS:
Treatment as usual
Unified Protocol
OTHER 
ASSESSMENTS:
Demographics X
ODSIS X X X X X
OASIS X X X X X
PANAS X X X X X
ACQ-R X X X X X
NEO-FFI X X X X X
QLI X X X X X
MI X X X X X
Treatment Preference X
OTS X X X X
Fig. 2 Study schedule of enrolment, interventions, and assessments
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individuals was calculated. However, this was increased by
20 patients after considering non-inferiority sample size
calculations.
Procedure
Randomization has been performed by a researcher un-
related to the study using a computer-generated
sequence (Randomizer). In the program, the researcher
generated 1 set of numbers with 220 numbers, which
had a 1-to-2 range. Randomization is stratified according
to the severity of the primary measures of depression
(BDI-II) [23, 24] and anxiety (BAI) [25, 26], using the
recommended cut-off in manuals. In the BDI-II, these
are 0–13 for normal, 14–19 for mild, 20–28 for moder-
ate, and for 29–63: severe depressive symptoms [24]. As
for anxiety symptoms (BAI), cut-off are 0–7 for normal,
10–18 for mild, 16–25 for moderate, and 26–63 for se-
vere [26]. Stratification is made to ensure a comparable
proportion of severely depressed and anxious individuals
in each group. For each subgroup (i.e., severe or less
severe depression and/or anxiety), participants are ran-
domly assigned to the UP or to TAU. In the UP condi-
tion, there are between 8 and 10 participants and 2
clinicians (therapist and co-therapist) per group. In the
TAU condition, participants receive individual sessions
with one therapist.
Eligibility criteria
Inclusion and exclusion criteria were set following
the recommendations made by the authors of the
UP [27] (Table 1).
Ethics
This study is carried out in accordance with the study
protocol, the Helsinki Declaration, and good clinical
practice. This non-inferiority, multicenter, randomized,
controlled clinical trial has been approved by ethical and
research committees of all collaborating centers: Hos-
pital General Clínico de Elda (N°. PUG-02-14), Hospital
Clínico Universitario de Valencia (N°. F-CE-GEva-15),
Hospital Universitario Dr. Peset (N°. CEIC 53/15), CSM
IIA Milagrosa (N°. Pyto2016/41), and Hospital Comarcal
de Vinaròs (N°. 0103–2016). Data handling is carried out
according to premises established by Spanish laws [28].
Security and confidentiality of participants’ data are
guaranteed by using alphanumeric codes (SUP001)
instead of names.
Therapists and interventions
Therapists participating in the study include licensed
psychologists with between 8 and 20 years of experience
in delivering CBT, clinical psychology residents with 2 to
4 years of experience, and doctoral students in clinical
psychology with between 3 and 5 years of experience.
Unified protocol in group format
Our research team has adapted the UP [8, 9] to imple-
ment it in group format in a public mental health setting
in Spain. This adaptation is composed of 12, two-hour
treatment sessions, at a rate of one session per week.
Treatment content, split by session, is shown in
Table 2.To encourage maximum fidelity to the protocol,
all therapists participating in this condition received a
UP training course prior to study onset, as well as
Table 1 Eligibility criteria
Inclusion criteria
1
Anxiety disorder, mood disorder, or adjustment disorder is the main diagnosis (most interfering and severe)a
2
The patient is over 18 years of age
3
The patient is fluent in the language in which therapy is performed (Spanish in the present study)
4
The patient is able to attend to the evaluation and treatment sessions and signs the informed consent form
5
Patients taking pharmacological treatment for their emotional disorder are asked to maintain the same dosages and medications for at least
3 months prior to enrolling in the study and during the whole treatmentb
Exclusion criteria
1
The patient presents a severe condition that would require to be prioritized for treatment, so that an interaction between both interventions
cannot be ruled out. These include a severe mental disorder (bipolar disorder, schizophrenia, or an organic mental disorder),suicide risk at the
time of assessment, or substance use in the last three months (excluding cannabis, coffee, and / or nicotine)
2
The patient has previously received 8 or more sessions of psychological treatment with clear and identifiable CBT principles within the past
5 years.
aThe following disorders will be included based on DSM-IV-TR diagnostic criteria [21]: major depression disorder, dysthymic disorder, panic disorder, agoraphobia,
obsessive-compulsive disorder, generalized anxiety disorder, posttraumatic stress disorder, social anxiety disorder, hypochondria, and adjustment disorders.
Patients with unspecified anxiety disorders and unspecified depressive disorders will also be included as they are frequent in public settings
bIf medication stability is not possible, the participant’s data will be treated separately in the analyses
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videoconference supervision before every session. The
course consisted of a 20-h group workshop divided in 3
sessions. Next, all therapists received an individual train-
ing during 12 therapy sessions. Depending on availabil-
ity, this individual training consisted of an online
supervision before sessions or it involved acting as a
co-therapist. Supervision is conducted by the leading
author, J.O., who has been certified UP Researcher/
Trainer by the Unified Protocol Institute.
Participants who miss one or more UP sessions receive
a phone call from the group therapist to explore the
reasons for non-attendance, as well as to encourage
reading the materials that summarize missed sessions.
Also, at the beginning of each session the therapist re-
views important contents of the past session to minimize
this effect of missed sessions.
Treatment as usual (TAU)
Individual CBT is the treatment of choice by psycholo-
gists and psychiatrists at the collaborating Public Mental
Health Centers and Primary Care Centers, together with
pharmacological treatment (i.e., antidepressants and / or
anxiolytics). Clinicians in this condition complete a
self-report sheet describing the characteristics of their
interventions with treatment modules as cues (psycho
education module, identification of negative thoughts,
breathing training, etc.), the average duration of sessions,
number of sessions delivered, and end-of-treatment date,
as well as information on the number of appointments
with the psychiatrist and pharmacological treatment
prescribed during the study. Information on the number
of appointments with the psychiatrist and pharmaco-
logical treatment prescribed during the study is also
collected for patients in the UP group following the
same procedure described for the CBT condition.
As opposed to the UP condition, in which the duration
of treatment is fixed (12 sessions), the usual practice in
Spanish public settings is that treatment ends when both
the clinician and the patient agree that the intervention
has been effective. This is not necessarily guided by
questionnaires or a diagnostic interview, but on clinical
judgment. Because the study goal is to compare a new
treatment (UP in a group format) with the usual practice
in Spanish public settings, the same procedure described
above will be used to determine the end of treatment in
the TAU condition and no specific end points (i.e., a
decrease in questionnaire scores) or number of sessions
will be imposed. Because this is likely to yield different
treatment durations between study conditions, the treat-
ment duration (number of sessions) will be used as a
covariate in the analyses.
Measures
The evaluation protocol is administered by therapists
in a paper and pencil format at the participant’s
health center in 5 different times: baseline, post-
treatment, and follow-ups at 3, 6, and 12 months. To
minimize biases, every administration of the diagnos-
tic interview is done by two different psychologists,
one face-to-face and the other by phone. Inter-rater
reliability will be calculated. Assessment instruments
include demographic characteristics (age, sex, educa-
tion, marital status, and work status), a diagnostic
interview, and well-established questionnaires for both
primary and secondary outcomes.
Primary outcomes
Severity of depression and anxiety symptoms are
assessed with the Beck Depression Inventory (BDI-II)
[23, 24] and the Beck Anxiety Inventory (BAI) [25, 26],
respectively.
In addition to symptoms, a current diagnosis of
anxiety and/or mood disorder is made with the lifetime
version of the Anxiety Disorders Interview Schedule for
DSM-IV (ADIS-IV-L) [4, 29]. The ADIS-IV-L is a semi-
structured interview based on the diagnostic criteria of
the Diagnostic and Statistical Manual of Mental Disorders
-4th ed. (DSM-IV-TR) [4]. We have not used the ADIS-5
because it is not available in Spanish yet.
Secondary outcomes
We administer the Overall Depression Severity and
Impairment Scale (ODSIS) [30] and the Overall Anxiety
Severity and Impairment Scale (OASIS) [31] weekly to
assess the severity of depressive and anxiety symptoms,
respectively. These measures are included to comple-
ment the results obtained with the BDI-II and the BAI,
as well as to obtain a continuous assessment. The Posi-
tive and Negative Affect Scale (PANAS) [32, 33] is
Table 2 Treatment content split by session
Session number Content
Session1 Motivation for change and commitment to treatment
Session2 Understanding the adaptability of emotions
Session3 Recognition and analysis of emotions
Session4 Emotional awareness training - I
Session5 Emotional awareness training - II
Session6 Cognitive flexibility- I
Session7 Cognitive flexibility- II
Session8 Emotional avoidance and emotion-driven behaviors
Session9 Consciousness and tolerance to physical sensations
Session10 Interoceptive and situational emotional exposure- I
Session11 Interoceptive and situational emotional exposure- II
Session12 Achievements, maintenance, and relapse prevention
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administered to evaluate positive and negative affect.
The perception of control over anxiety is assessed by
means of the Anxiety Control Questionnaire-Revised
(ACQ-R) [34, 35]. Personality is measured with the NEO
Five-Factor Inventory (NEO-FFI) [36], which offers a
rapid and general measure of the Big Five personality
traits: Neuroticism, Extraversion, Openness to experi-
ence, Agreeableness, and Conscientiousness. The Quality
of Life Index (QLI) [37] is used to evaluate several as-
pects of health-related quality of life (i.e., physical dis-
ability, emotional well-being, self-care and independent
functioning, occupational functioning, interpersonal
functioning, social emotional support, community and
services support, personal fulfillment, spiritual fulfill-
ment, and overall quality of life). Similarly, the Mal-
adjustment Inventory (MI) [38] is used to evaluate the
extent to which the subject’s current problems impact
negatively on different areas of daily life, namely, work,
social life, leisure time, relationship with the partner,
family life, and overall adjustment in daily activities.
Additionally, we created an ad hoc questionnaire, the
Treatment Opinion Scale (OTS), which is administered
to participants in both conditions. Our ad hoc question-
naire evaluates the quality of the intervention (i.e., “How
would you rate the quality of the treatment program you
have received?”) and that of its components (i.e., “Have
the techniques and exercises that we have practiced
helped you regulate your emotions properly?”). Also, it
measures the amount of discomfort experienced during
treatment (i.e., “To what extent has this treatment
caused you discomfort?”) and the experience of partici-
pating in a group format (i.e., “If you were to seek help
again, would you choose a group treatment program?”).
Some questions in the OTS use a4-point Likert scale
(0 = “poor” or “nothing” to 3 = “excellent” or “very
much”), while an 11-point response scale is selected in
some items (0 = “nothing” to 10 = “very much”).
All measures used in the study have been standardized
in Spanish. Administration time is between 90 and120
minutes for the ADIS-IV-L and approximately 90 min
for the primary and secondary outcomes altogether.
Analyses
First, we will calculate between-group differences in
baseline measures, to ensure that randomization resulted
in comparable groups. When normally distributed,
continuous data will be analyzed via t test. If the
Kolmogorov-Smirnov test indicates a non-normal distri-
bution, a Mann-Whitney U test will be preferred. A
chi-square test will be performed for categorical data.
Then, to compare the efficacy of treatments, we will use
a mixed-effects regression modeling with full informa-
tion maximum likely hood estimation. This method is
recommended over repeated-measures ANOVAs due to
its flexibility in handling missing data [39]. Group (TAU
or UP) will be used as the between-subject factor and
time (baseline, post-treatment, and follow-ups) as the
within-subject factor. Standardized effect sizes (Cohen’s
d) will be calculated both for within and between-group
analyses. Covariates will be demographic and clinical
variables that are not comparable between groups, as
exposed in the beginning of this section. Effect estima-
tors in the UP group will be adjusted to control for the
impact of group dependencies (i.e., homogenization of
response to treatment due to shared environment),
following the recommendations of Baldwin et al. [40].
To address problems of missing data or premature
dropouts, an intention-to-treat analysis will be used and
the most recent data will be imputed (last observation
carried forward approach). This analytic strategy will
only be performed with patients attending at least 50%
of sessions, as recommended in past research [41], and
with those responding to at least one of the post-
treatment assessments (i.e., end of treatment or follow-
ups) so that treatment effect may be captured by the last
observation. In addition to the last observation forward,
missing data in the UP group will also be replaced with
the CBT mean +/− the non-inferiority margin and miss-
ing data in the CBT group will be replaced with the UP
mean (i.e., bias toward inferiority) [42]. Results using a
last observation carried forward approach and a bias
toward inferiority imputation will be compared against a
completers-only strategy and all of them will be
reported. To ensure non-inferiority, a per-protocol ana-
lysis will also be conducted. Following FDA guidelines
[16], non-inferiority will be concluded if the upper
bound of the 95% CI for the effect estimate in the UP
condition is smaller than the non-inferiority margin
(50% of the effect estimate of individual CBT when
compared to placebo). Due to the non-inferiority design
(i.e., the Unified Protocol in a group format is not
worse than individual CBT), a one-sided confidence
interval will be used in the analyses. A post-hoc power
analysis with the primary outcomes will be conducted
at post-treatment and follow-ups using the sample size
and obtained effect size.
The researcher analyzing data, C.S.R., will be blind to
arm allocation. To ensure that, arms will be given arbi-
trary letters (A and B) in the database and only the lead
researcher, J.O., will know the correspondence between
study allocation arms and assigned arbitrary letters.
Reporting of results will follow the Consolidated
Standards of Reporting Trials (CONSORT) recommen-
dations [43].
Discussion
EDs have become a matter of public concern due to
their high prevalence and associated costs [6, 7, 44]. The
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UP has emerged as a promising form of CBT to be used
across diagnostic categories both in individual and group
format [8, 9]. Therefore, the study of a therapeutic ap-
proach that can be administered to several patients with
different disorders simultaneously, as in the present
study, may have important clinical implications for
countries.
The use of the UP in group format in public mental
health settings may have some advantages over trad-
itional individual CBT: 1) it may allow clinicians to use
the same treatment for a variety of psychological disor-
ders [8, 9, 12]; 2) it might help reduce existing waiting
lists as between 6 and 8 patients can be treated simul-
taneously, which would probably reduce the duration of
suffering in unattended patients; 3) in contexts similar
to the Spanish public system, where individual CBT is
the norm and therapy sessions occur at long intervals
(i.e., once a month) due to waiting lists, a UP-based
treatment program in group format can help increase
the frequency of sessions because more patients are
treated simultaneously, which may facilitate a more
rapid detection of patients’ problems during treatment;
4) finally, group therapy is known to report benefits for
the patient that are not obtained with individual treat-
ment, such as reducing isolation, facilitating social sup-
port, and learning from others’ experiences [45, 46],
which might enhance its efficiency. The present RCT
taps into the aforementioned aspects of treatment satis-
faction and effectiveness.
Our study has also some limitations. First, some people
who ask for treatment in the public mental health system
prefer individual treatment, which could be a barrier when
randomly assigned to a group format (i.e., dropout or
decreased satisfaction and efficacy of the UP). To control
for this, we will explore the effect of format preference
and format assignment on treatment adherence and ef-
fectiveness. Additionally, as conditions differ in terms of
type of therapy (CBT vs. UP) and format (individual vs.
group), it will be difficult to ascertain what was respon-
sible for the results. Despite the present study only seeks
to find whether the UP in a group format can be an alter-
native to the traditional psychological treatment in public
settings in Spain (i.e., individual CBT), results should be
interpreted with caution and no conclusions can be drawn
on whether results are due to differences in the type of
therapy, its format, or both. In line with the previous, it is
important to note that the usual treatment was not stabi-
lized across clinicians at centers (i.e., duration of sessions
and treatment) precisely to ensure that the newly tested
treatment, namely the UP in a group format, was com-
pared against the usual treatment in Public Mental Health
Settings in Spain. It is also important to note that, due the
multicenter nature of the study, interventions are con-
ducted by different clinicians, so implementation could
differ across centers. In order to minimize this effect, a
certified UP Researcher/Trainer, J.O., has been in charge
of the full treatment for the first two groups at all collab-
orating centers. All clinicians will act as co-therapists of
one group at their working center. Also, when they start
treatment they will receive a videoconference supervision
before every session by J.O. Despite this is done to
promote fidelity to the protocol, it is important to note
that assessment of fidelity is not performed by an inde-
pendent rater, so true fidelity cannot be ensured. Finally,
another shortcoming is that interviewers using the ADIS
are not blind to treatment arm. This was not possible due
to legal reasons (data collection at participating hospitals
had to be done by a psychologist/psychiatrist working at
the center). Due to time restrictions of psychiatrists, this
was done by psychologists, who were also in charge of
treatment. Despite this limitation, it is important to note
that the ADIS is an objective, structured interview, and
that on each assessment two interviews are independently
made by two different psychologists, which should reduce
the likelihood of biases.
Despite the aforementioned shortcomings, the present
study may have important clinical implications as it is
the first randomized, controlled clinical trial to test the
effectiveness of a transdiagnostic intervention in group
format for the treatment of EDs in public settings in
Spain. Results will reveal whether the use of the UP in
group format may serve to reduce existent waiting lists
without decreasing the effectiveness of interventions
(non-inferior to TAU).This would have important impli-
cations for patients, as it would possibly allow treat-
ments to be more intensive (i.e., on a weekly basis
instead of monthly) thanks to the simultaneous treat-
ment of an increased number of patients.
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